Bioenvision (NASDAQ:BIVN)
Historical Stock Chart
From Jul 2019 to Jul 2024
Bioenvision, Inc. (Nasdaq:BIVN) today announced Christopher B. Wood,
M.D., chairman and chief executive officer of the Company, will be
giving a presentation at the CIBC World Markets Annual Biotechnology &
Specialty Pharmaceuticals Conference on Thursday, April 12, 2007 at
2:30pm EDT. The conference is being held at the Millennium Broadway
hotel in New York City.
The presentation will be webcast live and available on the webcast
section of the Company’s website, www.bioenvision.com.
The webcast will be archived and the link will remain active through
April 26, 2007.
About Bioenvision
Bioenvision's primary focus is the acquisition, development and
marketing of compounds and technologies for the treatment of cancer.
Bioenvision has a broad pipeline of products for the treatment of
cancer, including: Evoltra®,
Modrenal® (for which
Bioenvision has obtained regulatory approval for marketing in the United
Kingdom for the treatment of post-menopausal breast cancer following
relapse to initial hormone therapy), and other products. Bioenvision is
also developing Suvus®
which is currently in clinical development for refractory chronic
hepatitis C infection. For more information on Bioenvision please visit
our website at www.bioenvision.com.
Certain statements contained herein are "forward-looking" statements
(as such term is defined in the Private Securities Litigation Reform Act
of 1995). Because these statements include risks and uncertainties,
actual results may differ materially from those expressed or implied by
such forward-looking statements. Specifically, factors that could cause
actual results to differ materially from those expressed or implied by
such forward-looking statements include, but are not limited to: risks
associated with preclinical and clinical developments in the
biopharmaceutical industry in general and in Bioenvision's compounds
under development in particular; the potential failure of Bioenvision's
compounds under development to prove safe and effective for treatment of
disease; uncertainties inherent in the early stage of Bioenvision's
compounds under development; failure to successfully implement or
complete clinical trials; failure to receive marketing clearance from
regulatory agencies for our compounds under development; acquisitions,
divestitures, mergers, licenses or strategic initiatives that change
Bioenvision's business, structure or projections; the development of
competing products; uncertainties related to Bioenvision's dependence on
third parties and partners; and those risks described in Bioenvision's
filings with the SEC. Bioenvision disclaims any obligation to update
these forward-looking statements.